This clinical trial is focused on studying the effects of a new treatment for Ulcerative Colitis, a condition that causes inflammation and sores in the digestive tract. The treatment being tested is a medication known as GS-5290, which is taken in the form of film-coated tablets. The study aims to evaluate how effective and safe this medication is for people with moderately to severely active ulcerative colitis.

Participants in the study will be randomly assigned to receive either the GS-5290 tablets or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The main goal is to see if the medication can help reduce the symptoms of ulcerative colitis by Week 12 of the study.

The study will last for a period of 64 weeks, during which participants will take the medication orally. The researchers will monitor the participants’ health and symptoms throughout the study to assess the medication’s impact. The study will also look at secondary outcomes, such as achieving clinical remission and improvements in the condition of the colon as seen through endoscopic examinations. The results will help determine if GS-5290 is a viable treatment option for those suffering from ulcerative colitis.